Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS (USED IN) OPERATING ACTIVITIES
Net loss	$ (7,485,738)	$ (5,835,407)
Adjustments to reconcile net loss to net cash (used in) operating activities
Depreciation and amortization	12,482	515,071
Loss on disposal of fixed assets	49,278	6,056
Employee and director stock-based compensation - non-cash	1,132,616	$ 291,200
Stock warrant expense - non-cash	$ 261,570
Deferred income taxes		$ (238,129)
Loss on settlement of note payable - related parties		1,829,562
Loss on settlement of note payable		876,543
Changes in other assets and liabilities affecting cash flows used in operating activities
Prepaid expenses, deposits and other assets	$ 667,653	461,933
Accounts payable and accrued liabilities	229,240	(3,027,926)
Net cash (used in) operating activities	(5,132,899)	$ (5,121,098)
CASH FLOWS (USED IN) INVESTING ACTIVITIES
Investment in Or-Genix	(250,000)
Purchase of fixed assets	(28,227)
Net cash (used in) investing activities	$ (278,227)
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES
Proceeds on notes payable		$ 400,000
Proceeds from issuance of common stock		31,605,727
Net cash provided by financing activities		32,005,727
NET (DECREASE) INCREASE CASH AND CASH EQUIVALENTS	$ (5,411,126)	26,884,629
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	21,883,887	254,964
CASH AND CASH EQUIVALENTS AT END OF PERIOD	$ 16,472,761	27,139,593
NON-CASH INVESTING AND FINANCING ACTIVITIES
Acquisition of business in exchange for common stock		6,800,000
Conversion of accounts payable to notes payable related to Company's outside law firm		407,998
Issuance of shares of common stock and stock warrants as payment of notes payable - related parties		1,105,475
Issuance of shares of common stock and stock warrants as payment of notes payable		517,945
Issuance of shares of common stock and stock warrants as payment of accounts payable and accrued liabilities		$ 1,361,404